AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire to Assess Adherence to Aromatase Inhibitors
Description: Questionnaire to Assess Adherence to Aromatase Inhibitors
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demographics Questionnaire
Description: Demographics Questionnaire
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographics Questionnaire
Description: Demographics Questionnaire
Study NCT05014919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Tablets
Study NCT05014919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study NCT05570162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes educational program
Description: 30-minute long diabetes educational program
Study NCT06583655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND(clinical low risk)
Description: treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
Study NCT06583655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND(clinical high risk, genomic low risk)
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
Study NCT06583655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND alone ,clinical high risk and genomic high risk group
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
Study NCT06583655 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
Study NCT06583343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
Study NCT06583343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
Study NCT04708847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GYM329
Description: GYM329 subcutaneous injection
Study NCT04708847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT05218109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: transcutaneous vagus nerve stimulation
Study NCT05218109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application
Study NCT05218109 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application
Study NCT05218109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application
Study NCT05218109 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tVNS
Description: sham transcutaneous vagus nerve stimulation
Study NCT05218109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number Puzzle
Description: Control number puzzle task delivered via mobile device
Study NCT04846998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9003
Description: Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it.
Study NCT04846998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9003A
Description: Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state
Study NCT04657991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT04657991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT06460363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (TACS)
Description: Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
Study NCT05781451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
Study NCT06501976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: 2.6 mg/m2 , Given IV, every 21 days
Study NCT06501976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic radiotherapy
Study NCT06460363 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TACS
Description: Sham treatment with few seconds of actual electrical current and same electrode configuration
Study NCT04379830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Energy Diet
Description: Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
Study NCT05006755 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
Study NCT05006755 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
Study NCT06274177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
Study NCT05406713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg intravenously
Study NCT05641116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: 24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
Study NCT05641116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
Study NCT04951193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
Study NCT04951193 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
Study NCT05712681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet after the meal
Study NCT05712681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: R : JP-1366 20mg tablet under fasting condition
Study NCT05479370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT05479370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT05479370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT05164653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril Valsartan Sodium Hydrate
Description: Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation.
Study NCT05164653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
Study NCT05789290 — intervention group
Intervention type: DEVICE
Intervention: Hilotherm cryocompression device
Description: An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
Study NCT05422482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1123
Description: ICV-administered Hunterase, Idursulfase-ß
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121
Description: PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121
Description: PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400
Description: PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGDM1400
Description: PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Study NCT04983030 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRC07-523LS
Description: VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Study NCT06638905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babor Ultimate ECM Repair Serum
Description: The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Study NCT06638905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babor Cure Cream
Description: Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Study NCT06644443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-GPRC5D CAR-T cells
Description: patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
Study NCT06645171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre drink
Description: One drink will be tested
Study NCT06640478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUTRI-Beta Counseling
Description: Dietary Counseling focused on anti-inflammatory foods
Study NCT06640478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard dietary counseling
Description: Standard of Care therapy: Nutrition counseling per the ADA clinical guidelines and USDA MyPlate model
Study NCT06640478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Free weekly produce foods
Description: Free weekly produce
Study NCT05617885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
Study NCT05617885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.
Study NCT05617885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Leuprolide Acetate
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Study NCT05617885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Goserelin
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
Study NCT05617885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
Study NCT06161493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
Study NCT06161493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
Study NCT05946551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
Study NCT05946551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
Study NCT05946551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine Placebo
Description: The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
Study NCT05946551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine Placebo
Description: The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
Study NCT06114368 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for the treatment of Acute Achilles tendon rupture
Description: Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
Study NCT05427929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NVR 4mm Edi catheter
Description: Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
Study NCT05116137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit-based resistance exercise (CRT)
Description: CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
Study NCT05136495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeinated coffee - decaffeinated coffee
Description: Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
Study NCT05995574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: avatar communication training
Description: Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
Study NCT06111508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Description: A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
Study NCT05165238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of four week coaching program on dietary habits
Description: A registered dietitian will provide dietary coaching via online groups to participants.
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6 Continuous Glucose Monitoring
Description: Collection of glucose data
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitoring
Description: Collection of glucose data
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEDISAFE WITH External Insulin Pump
Description: Insulin delivery
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDISAFE WITH External Insulin Pump
Description: Insulin delivery
Study NCT04725591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diabeloop Software (Model predictive control)
Description: Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study NCT06681480 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: figure-of-eight sham rTMS coil device
Description: rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
Study NCT06680804 — intervention group
Intervention type: OTHER
Intervention: chance for vaginal delivery.
Description: chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy